Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCVax
- Development stage
- Unknown
- Lead developer
- Northwest Biotherapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intratumoral
01
Overview
DCVax is a platform of personalized (autologous) dendritic cell-based cancer vaccines developed by Northwest Biotherapeutics. The technology involves isolating a patient's precursor immune cells (monocytes) from the blood via leukapheresis, maturing them into dendritic cells, and then 'educating' or pulsing them with tumor-specific antigens. These antigens can be derived from the patient's own tumor lysate (as in DCVax-L) or specific viral/tumor antigens (as in HPV.DCVax). Once re-administered to the patient, typically via intradermal injection, these activated dendritic cells present the antigens to T cells, triggering a systemic and durable immune response against the cancer. The lead candidate, DCVax-L, has demonstrated significant improvements in overall survival in Phase 3 trials for glioblastoma multiforme (GBM). DCVax-Direct is a variant designed for intratumoral injection into various solid tumors that are not easily resectable.
- Brand names
- DCVaxDCVax-LDCVax-DirectDCVax-Prostate
- Other names
- HPV.DCVaxdendritic cell vaccinationDCvax
02
Targets
MHC I (MHC class I})γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on DCVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCVax.